ASC participation for colorectal surgeons: endoscopy and select procedures

ASC Ownership and K-1 Tax Structuring

Participating in an Ambulatory Surgery Center (ASC) isn’t just a clinical decision; it’s a significant financial one that introduces you to the world of partnership taxation via the Schedule K-1. When you buy into an ASC, you become a partner in a pass-through entity. The center itself doesn’t pay income tax; instead, profits and losses are “passed through” to the partners, who report them on their personal tax returns. This income arrives on a K-1, separate from the W-2 salary you might draw from your surgical practice.

The first critical distinction to understand is active versus passive participation, governed by IRS §469. If you are an active participant—meaning you meet one of the IRS’s material participation tests, such as spending more than 500 hours per year working in the ASC—then any losses the ASC might generate (especially in early years due to startup costs or accelerated depreciation) can generally be used to offset your active income from your surgical practice. This can be a powerful tax shield.

Here’s the trap: If you are merely a passive investor and don’t meet the material participation criteria, those same ASC losses are considered “passive losses.” You can only deduct them against passive income, not against your high W-2 salary. Most of us don’t have significant passive income, so those losses get suspended and carried forward indefinitely, providing no immediate tax benefit. For a colorectal surgeon performing cases at the center, meeting the material participation standard is usually straightforward, but it requires diligent record-keeping.

Your buy-in structure also has major tax implications. If you finance your buy-in, the debt increases your “tax basis” in the partnership, which is the amount you have at risk. Your ability to deduct losses is limited to your basis. A common strategy involves taking a reasonable salary from your surgical group (the PC) and receiving the majority of the ASC’s profit as a K-1 distribution. This can reduce payroll taxes (FICA/Medicare) on the distribution portion. Modeling these scenarios is complex, which is why a formal ASC/OBL feasibility advisory engagement is essential before signing any documents. They can project not just the clinical revenue but the tax implications of the deal structure.

The 199A QBI Deduction: A Great Idea That Most Surgeons Can’t Use

When the Tax Cuts and Jobs Act (TCJA) of 2017 was passed, one of its centerpieces was the new §199A Qualified Business Income (QBI) deduction. It allows owners of pass-through businesses (like partnerships, S-corps, and sole proprietorships) to deduct up to 20% of their business income, a significant tax break. On the surface, this sounds like a huge win for physician-owners of practices and ASCs.

However, the law includes a major exception that directly impacts us. The practice of medicine is defined as a “Specified Service Trade or Business” (SSTB). For SSTBs, the QBI deduction is phased out and ultimately eliminated for high-income earners. For the 2026 tax year, this phase-out begins at a taxable income of approximately $394,000 for single filers and $787,000 for those married filing jointly. Once your taxable income exceeds these thresholds, the 20% deduction is gone completely.

Let’s be direct: A partner-track colorectal surgeon, especially one with ASC ownership, will almost certainly have a household income that blows past these phase-out limits. The planning trap here is wasting time and energy trying to contort your finances to qualify for a deduction that was never designed for you. Most of us figured this out the hard way after a frustrating conversation with our CPA.

Instead of mourning the loss of the QBI deduction, view this as a clear signal. It tells you that standard, small-business tax planning isn’t enough. You must pivot to more powerful, sophisticated strategies that are specifically designed for high-income professionals. The rest of this article focuses on those strategies—the ones that actually move the needle when QBI is off the table.

Commercial Medical Real Estate: The ‘Prop-Co/Op-Co’ Model

One of the most effective tax and wealth-building strategies available to physician groups is owning the real estate where you practice. This is typically done through a “Prop-Co/Op-Co” (Property Company / Operating Company) structure. Here’s the sequence:

1. The surgeons form a separate entity, usually a multi-member LLC, to act as the “Prop-Co.” This LLC buys the medical office building or ASC facility.
2. Your medical practice, the “Op-Co,” signs a formal, triple-net (NNN) lease agreement to rent the building from your Prop-Co at a fair market rate.

This simple separation creates multiple financial benefits. The Op-Co (your practice) deducts the rent it pays as a standard business expense, reducing its taxable income. The Prop-Co (your real estate LLC) receives that rent as income. While this might seem like just moving money from one pocket to another, the real magic happens within the Prop-Co.

The Prop-Co can take massive non-cash deductions for depreciation on the building. By commissioning a cost segregation study, an engineering firm can break the building down into its components (e.g., electrical, plumbing, carpeting, fixtures) and accelerate the depreciation on these shorter-lived assets. This front-loads your tax deductions, often creating a large “paper loss” in the real estate entity for the first several years, even if the property is cash-flow positive.

Here is the advanced planning move and a common trap. By default, rental real estate is a passive activity. As we discussed earlier, passive losses can’t offset active surgical income. However, under IRS §469(c)(7), if your spouse can qualify for Real Estate Professional Status (REPS), those real estate losses become non-passive. To qualify, your spouse must spend more than 750 hours per year in real property trades or businesses, and this must represent more than half of their total working time. If they meet this test (and you file jointly), the paper losses from your medical building can be used to directly shield your high surgical income from taxes. This is one of the most powerful tax shelters available to high-income physicians.

Stacking a Cash Balance Plan on Your 401(k)

By the time you’re a partner, you’re likely already maxing out your 401(k) and any associated profit-sharing plan, which allows you to contribute a combined total of around $76,500 per year (2026 estimate). That’s a great start, but for a high-earning surgeon, it often isn’t enough to meaningfully reduce your tax burden or accelerate your retirement savings.

Enter the cash balance plan. This is a type of IRS-qualified defined-benefit pension plan that functions like a supercharged 401(k). While a 401(k) has fixed contribution limits, a cash balance plan’s limits are determined by an actuary based on your age, income, and target retirement benefit. For physicians in their peak earning years (40s, 50s, and 60s), this allows for massive pre-tax contributions. It is not uncommon for a surgeon to defer an additional $100,000, $200,000, or even over $300,000 per year into one of these plans—all of it fully tax-deductible.

Here’s how it works in practice. Your group’s retirement offerings would be a “stack” of two plans:

1. A 401(k) / Profit-Sharing Plan: This is the base layer, where you and other employees contribute.
2. A Cash Balance Plan: This is the overlay, primarily for the partners/owners. The plan document is written to favor older, higher-income partners, allowing them to contribute far more than younger staff (this is legal and a key feature of the plan design).

The planning trap here is assuming it’s too complex or only for massive groups. I’ve seen this implemented successfully in groups with just a few partners. The key is that the partners must be committed to making the large contributions required. The contributions are mandatory once the plan is established for the year. You can’t decide on a whim to contribute less. However, the tax savings are immense. Deferring an extra $200,000 in a 45% combined federal and state tax bracket means an immediate tax savings of $90,000 per year. This is a strategy that can single-handedly change your financial trajectory, allowing you to build wealth in a tax-protected account at a rate that is otherwise impossible.

Putting It All Together: From Endoscopy Rates to Tax Alpha

For a colorectal surgeon, the opportunity in an ASC is twofold. First is the clinical and operational advantage of controlling your environment for endoscopy and other select outpatient procedures. This requires a deep understanding of case-level profitability, which starts with knowing your local payer landscape. Using a tool with CenterIQ rate intelligence is no longer optional; it’s the foundation of a sound pro forma. You need to know what you’ll be paid per CPT code before you ever break ground.

The second, and equally important, opportunity is the financial architecture you build around the ASC. As we’ve seen, because your income as a surgeon disqualifies you from the simple §199A QBI deduction, you are forced to be more sophisticated. You must graduate to strategies that are purpose-built for high earners.

This means layering your financial life:

• Your W-2/1099 income from your professional work.
• Your K-1 income from the ASC partnership.
• The tax-sheltered growth from a stacked 401(k) and cash balance plan.
• The long-term wealth creation and tax-loss generation from owning the medical real estate via a separate LLC.

Each of these elements works together. The real estate losses shield the surgical income, while the cash balance plan defers a massive portion of what’s left. This is how you generate “tax alpha”—the excess return created by smart tax planning. It requires a proactive approach and a team of advisors who understand the specific financial ecosystem of a partner-track surgeon. The path from performing a colonoscopy to building durable wealth is paved with these deliberate, informed financial structures.

Reviewed by Pouyan Golshani, MD, Interventional Radiologist — May 21, 2026